Q4 2024 Cytosorbents Corp Earnings Call Transcript
Key Points
- CytoSorbents Corp (CTSO) reported a 25% increase in fourth-quarter product revenue, reaching $9.2 million, and a 15% year-over-year growth in full-year product revenue for 2024.
- The company's core product, CytoSorb, has been utilized in over 270,000 devices across more than 70 countries, driving significant international sales.
- CytoSorbents Corp (CTSO) maintained a healthy product gross margin of 71%, reflecting the strength of their business model.
- The company strengthened its financial position with a $20 million debt facility and a successful shareholder rights offering, increasing liquidity by $12.3 million.
- CytoSorbents Corp (CTSO) is actively preparing for the potential commercial launch of DrugSorb-ATR in the US and Canada, with a total addressable market opportunity of $300 million, potentially growing to over a billion dollars.
- CytoSorbents Corp (CTSO) experienced flat growth in direct sales in Germany, which is their largest market, for the second consecutive year.
- The company identified misstatements in inventory and non-cash stock compensation, leading to a restatement of their 2023 and 2024 financial reports.
- There is a material weakness in CytoSorbents Corp (CTSO)'s internal controls over financial reporting, which they aim to remediate during the current calendar year.
- The reorganization of the sales team in Germany is expected to cause short-term disruption, resulting in modestly lower product sales in the first quarter of 2025.
- CytoSorbents Corp (CTSO) anticipates that the DrugSorb-ATR business will not be immediately profitable upon launch due to initial investments in commercial capabilities.
Good afternoon, ladies and gentlemen, and welcome to the CytoSorbent Corp. fourth quarter and full year 2024 financial results and recent business highlights conference call. (Operator Instructions) This call is being recorded on Monday, March 31, 2025.
I would not like to turn the conference over to Adanna Alexander. Please go ahead.
Thank you, John, and good afternoon, everyone. Welcome to Fiorin's fourth quarter and full year 2024 financial results and business highlights conference call. Joining me today from the company for the prepared remarks are Dr. Philip Chan, Chief Executive Officer; and Pete Mariani, Chief Financial Officer.
Before I turn the call over to Doctor Chan, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore, the company claims protection under the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
